Identification of methylation-silenced genes in colorectal cancer cell lines: Genomic screening using oligonucleotide arrays

References

• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159–70
   PubMed Web of Science ®Google Scholar
• White RL. Tumor suppressing pathways. Cell 1998; 92: 591–2
   PubMedGoogle Scholar
• Peltomaki P, de la Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 1997; 71: 93–119
   PubMedGoogle Scholar
• Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141–96
   PubMed Web of Science ®Google Scholar
• Jones PA. The DNA methylation paradox. Trends Genet 1999; 15: 34–7
   PubMed Web of Science ®Google Scholar
• Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59: 2029–33
   PubMed Web of Science ®Google Scholar
• Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60: 4366–71
   PubMed Web of Science ®Google Scholar
• Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis 2000; 21: 461–7
   PubMed Web of Science ®Google Scholar
• Xiong Z, Wu AH, Bender CM, Tsao JL, Blake C, Shibata D, et al. Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. Cancer Epidemiol Biomark Prev 2001; 10: 799–803
   PubMedGoogle Scholar
• Herman JG. Hypermethylation pathways to colorectal cancer. Implications for prevention and detection. Gastroenterol Clin North Am 2002; 31: 945–58
   PubMedGoogle Scholar
• Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 1999; 5: 2450–4
   PubMed Web of Science ®Google Scholar
• Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210–9
   PubMed Web of Science ®Google Scholar
• Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463–7
   PubMed Web of Science ®Google Scholar
• Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1–7
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–54
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141–9
   PubMed Web of Science ®Google Scholar
• Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005; 65: 4963–8
   PubMed Web of Science ®Google Scholar
• Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004; 64: 5982–7
   Google Scholar
• Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64: 4442–52
   PubMed Web of Science ®Google Scholar
• Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261–82
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22–32
   PubMed Web of Science ®Google Scholar
• Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003; 194: 272–88
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999; 59: 1445–8
   PubMed Web of Science ®Google Scholar
• Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001; 20: 7699–709
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim S-P, Gabrielson E, Park YB, Park JW, Kwon tK. Int J Cancer 2005;116:200–6.
   PubMedGoogle Scholar
• Chen ME, Lin SH, Chung LWK, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. J Biol Chem 1988; 273: 17618–25
   Google Scholar
• Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006; 119: 1338–44
   PubMed Web of Science ®Google Scholar
• Wilkinson K, Lee K, Deshpande S, Duerksen-Hughes P, Boss J, Pohl J. The neuron-specific protein PGP9.5 is a ubiquitin carboxy-terminal hydrolase. Science 1989; 246: 670–3
   PubMed Web of Science ®Google Scholar
• Liu Y, Fallon L, Lashuel H, Liu Z, Lansbury P, Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111: 209–18
   PubMed Web of Science ®Google Scholar
• Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451–2
   PubMed Web of Science ®Google Scholar
• Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47–51
   PubMed Web of Science ®Google Scholar
• Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000; 6: 4764–7
   PubMed Web of Science ®Google Scholar
• Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, et al. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterol 2003; 50: 1278–80
   PubMedGoogle Scholar
• Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, John L, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735–42
   PubMed Web of Science ®Google Scholar
• Diana LM, Yamashita K, Tokumaru Y, Mimori K, David LH, Tanaka Y, et al. PGP9.5 Promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005; 65: 4963–8
   PubMedGoogle Scholar
• Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002; 8: 192–5
   PubMed Web of Science ®Google Scholar
• Leibovitz A, Stinson JC, McCombs WB, MeCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines”. Cancer Res 1976; 36: 4562–9
   PubMed Web of Science ®Google Scholar